About: EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLL Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLL
Creator	Hammerschmidt, Wolfgang Jochum, Simon Mocikat, Ralph Ruiss, Romana Zeidler, Reinhard
Source	PMC
abstract	gp350, the major envelope protein of Epstein-Barr-Virus, confers B-cell tropism to the virus by interacting with the B lineage marker CD21. Here we utilize gp350 to generate tailored exosomes with an identical tropism. These exosomes can be used for the targeted co-transfer of functional proteins to normal and malignant human B cells. We demonstrate here the co-transfer of functional CD154 protein on tailored gp350+ exosomes to malignant B blasts from patients with B chronic lymphocytic leukemia (B-CLL), rendering B blasts immunogenic to tumor-reactive autologous T cells. Intriguingly, engulfment of gp350+ exosomes by B-CLL cells and presentation of gp350-derived peptides also re-stimulated EBV-specific T cells and redirected the strong antiviral cellular immune response in patients to leukemic B cells. In essence, we show that gp350 alone confers B-cell tropism to exosomes and that these exosomes can be further engineered to simultaneously trigger virus- and tumor-specific immune responses. The simultaneous exploitation of gp350 as a tropism molecule for tailored exosomes and as a neo-antigen in malignant B cells provides a novel attractive strategy for immunotherapy of B-CLL and other B-cell malignancies.
has issue date	2011-10-10(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0025294
bibo:pmid	22022385
has license	cc-by
sha1sum (hex)	ca866226d436ba4c39fe854f9cc568f08638868d
schema:url	https://doi.org/10.1371/journal.pone.0025294
resource representing a document's title	EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLL
has PubMed Central identifier	PMC3189918
has PubMed identifier	22022385
schema:publication	PLoS One
resource representing a document's body	covid:ca866226d436ba4c39fe854f9cc568f08638868d#body_text
is schema:about of	named entity 'TAILORED' named entity 'immunotherapy' named entity 'autologous' named entity 'B-CLL' named entity 'exploitation' named entity 'exosomes' named entity 'tailored' named entity 'presentation' named entity 'malignant' named entity 'functional' named entity 'B Cells' named entity 'ANTIGEN' covid:arg/ca866226d436ba4c39fe854f9cc568f08638868d named entity 'EXOSOMES' named entity 'B CELLS' named entity 'TARGETED' named entity 'SIMULTANEOUSLY' named entity 'TAILORED' named entity 'B CHRONIC LYMPHOCYTIC LEUKEMIA' named entity 'HUMAN' named entity 'PROVIDES' named entity 'RENDERING' named entity 'CO-TRANSFER' named entity 'DERIVED' named entity 'EBV' named entity 'ESSENCE' named entity 'USED' named entity 'LINEAGE' named entity 'REACTIVE' named entity 'MAJOR' named entity 'CD21' named entity 'STIMULATED' named entity 'EPSTEIN-BARR-VIRUS' named entity 'AUTOLOGOUS' named entity 'MALIGNANCIES' named entity 'PEPTIDES' named entity 'TROPISM' named entity 'ATTRACTIVE' named entity 'B-CELL' named entity 'NEW' named entity 'B CELLS' named entity 'MALIGNANT' named entity 'THESE' named entity 'IMMUNOGENIC' named entity 'MARKER' named entity 'NOVEL' named entity 'CELLULAR IMMUNE RESPONSE' named entity 'IMMUNOTHERAPY' named entity 'ENVELOPE PROTEIN' named entity 'GENERATE' named entity 'CELLS' named entity 'FUNCTIONAL' named entity 'T CELLS' named entity 'ANTIVIRAL' named entity 'TRIGGER' named entity 'TUMOR' named entity 'EBV' named entity 'TROPISM' named entity 'OPTION' named entity 'IS A' named entity 'NORMAL' named entity 'MALIGNANT' named entity 'TREATMENT' named entity 'NEO' named entity 'INTERACTING' named entity 'EXOSOMES' named entity 'BLASTS' named entity 'NEO' named entity 'NORMAL' named entity 'HERE' named entity 'IDENTICAL' named entity 'SIMULTANEOUS' named entity 'VIRUS' named entity 'SPECIFIC' named entity 'PROTEINS' named entity 'PROTEIN ' named entity 'B-CLL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software